ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine

Bookmark and Share
Published: 11 Dec 2020
Views: 88
Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy

Dr Fontanna speaks to ecancer about a recent study presented at ASH 2020 about ETNK1 mutations in atypical chronic myeloid leukaemia induce a mutator phenotype that can be reverted with phosphoethanolamine.

She first talks about what the study as about saying that in this study they investigated the specific role of these mutations by using cellular CRISPR/Cas9 and ETNK1 overexpression models as well as a CML patients' samples. She says that this study showed that mutated ETNK1 causes a significant increase in mitochondrial activity and in ROS production.

Dr Fontanna further explains the key results and talks about how these results can impact CML treatment in the future.